Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Several other research firms have also issued reports on TENX. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Trading Up 0.8 %

NASDAQ TENX opened at $6.41 on Thursday. The firm’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $5.25. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Institutional Trading of Tenax Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $1,026,000. Vestal Point Capital LP bought a new stake in shares of Tenax Therapeutics during the third quarter worth $288,000. Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the third quarter worth $173,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the third quarter worth $101,000. Finally, Millennium Management LLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $166,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.